A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy

OncoTargets and Therapy

Volumn 8, Issue , 2015, Pages 3561-3564

  Williams, Casey B ^a   McMahon, Caitlin ^b   Ali, Siraj M ^b   Abramovitz, Mark ^a   Williams, Kirstin A ^a   Klein, Jessica ^a   McKean, Heidi ^a   Yelensky, Roman ^b   George, Thomas J ^c   Elvin, Julia A ^b   Soman, Salil ^d   Lipson, Doron ^b   Chmielecki, Juliann ^b   Morosini, Deborah ^b   Miller, Vincent A ^b   Stephens, Philip J ^b   Ross, Jeffrey S ^b,e   Leyland Jones, Brian ^a  

^a Avera Health   (United States)

^b FOUNDATION MEDICINE   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e ALBANY MEDICAL COLLEGE   (United States)

Author keywords

BRAF mutations; Colorectal adenocarcinoma; Combination targeted therapy; Oxaliplatin

Indexed keywords

B RAF KINASE; CARCINOEMBRYONIC ANTIGEN; DABRAFENIB; OXALIPLATIN; TRAMETINIB;

ABDOMINAL PAIN; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CASE REPORT; CELIAC DISEASE; CHILL; CLINICAL FEATURE; COLONOSCOPY; CONTRAST ENHANCEMENT; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG RESPONSE; DRUG SAFETY; FEMALE; FEVER; GENE MUTATION; HUMAN; HUMAN TISSUE; METASTATIC COLORECTAL CANCER; RASH;

EID: 84949650564     PISSN: 11786930     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S90766     Document Type: Article

References (15)

1. Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013; 31(11): 1023-1031.
2. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487(7407): 330-337.
3. Kemeny NE. Treatment of metastatic colon cancer: "the times they are A-changing". J Clin Oncol. 2013; 31(16): 1913-1916.
4. Connolly K, Brungs D, Szeto E, et al. Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAF V600E-mutatnt metastatic colorectal carcinoma. Curr Oncol. 2014; 21: 151-154.
5. Corcoran RB, Atreya CE, Falchook GS, et al. Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600E-mutant colorectal cancer. J Clin Oncol. Epub 2015 Sept 21.
6. Yaeger R, Cercek A, O'Reilly EM, et al. Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutation metastatic colorectal cancer patients. J Clin Oncol. 2015; 21(6): 1313-1320.
7. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417(6892): 949-954.
8. Gonsalves WI, Mahoney MR, Sargent DJ, et al; Alliance for Clinical Trials in Oncology. Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. J Natl Cancer Inst. 2014; 106(7).
9. Karagkounis G, Torbenson MS, Daniel HD, et al. Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Cancer. 2013; 119(23): 4137-4144.
10. Teng HW, Huang YC, Lin JK, et al. BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy. J Surg Oncol. 2012; 106(2): 123-129.
11. Corcoran RB, Ebi H, Turke AB, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012; 2(3): 227-235.
12. Straussman R, Morikawa T, Shee K, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012; 487: 500-504.
13. Ahronian LG, Sennott EM, Van Allen EM, et al. Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations. Cancer Discov. 2015; 5(4): 358-367.
14. Corcoran RB, Atreya CE, Falchook GS, et al. Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): updated efficacy and biomarker analysis. J Clin Oncol. 2014; 32: 5s (suppl; abstr 3517).
15. Souglakos J, Philips J, Wang R, et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer. 2009; 101(3): 465-472.